NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

NCT06345300 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Pancreatic Cancer

Interventions

DRUG: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab
DRUG: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]